불안장애 및 우울증 치료 시장 규모, 점유율, 동향 분석 보고서 : 약물 유형별, 적응증별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Anxiety Disorders And Depression Treatment Market Size, Share & Trends Analysis Report By Drug Type, By Indication (Depression, Anxiety), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

불안장애 및 우울증 치료 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 불안장애 및 우울증 치료제 시장 규모는 2030년까지 192억 8,000만 달러에 달할 것으로 추정되며, 2025-2030년까지 연평균 3.8%의 성장률을 기록할 것으로 예상됩니다.

전 세계 우울증 유병률의 증가는 향후 몇 년 동안 시장 성장을 촉진할 것으로 예상됩니다. 최근 몇 년 동안 항우울제 수요는 장비 및 심리치료의 채택이 증가함에 따라 감소하고 있습니다.

우울증에 취약한 노년층의 증가와 공포증, 범불안장애와 같은 불안장애의 급증은 예측 기간 동안 정신질환을 치료하기 위한 항우울제 수요 확대에 더욱 기여하고 있습니다. 또한, 뇌 자극에 사용되는 의료용 임플란트, 스마트폰 기반 애플리케이션을 이용한 가상현실 노출 요법 등 기술적으로 진보된 치료법의 도입은 환자들에게 혁신적인 치료 옵션을 제공하고 있습니다.

불안장애 및 우울증 치료 시장 보고서 하이라이트

• 항우울제 부문은 2024년 32.4%의 가장 높은 매출 점유율을 차지하며 시장을 장악했습니다.
• 불안증은 2024년 55.4%의 매출 점유율을 차지하며 시장을 주도했습니다. 이는 기성 경제권과 성장 경제권 모두에서 공포증, 사회불안장애, 기타 유사 질환이 증가하고 있기 때문입니다.
• 소매 약국 부문은 환자들이 가깝고 신뢰할 수 있는 약국을 선호하기 때문에 2024년 55.4%의 가장 큰 시장 점유율을 차지했습니다.
• 북미 불안장애 및 우울증 치료 시장은 2024년 37.6%의 매출 점유율로 세계 시장을 장악했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 불안장애 및 우울증 치료 시장 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 산업 분석 - Porter's Five Forces 분석
  • PESTLE 분석
  • 파이프라인 분석

제4장 불안장애 및 우울증 치료 시장 : 약물 유형별 비즈니스 분석

• 약물 유형별 시장 점유율, 2024년과 2030년
• 약물 유형 부문 대시보드
• 시장 규모와 예측과 동향 분석, 약물 유형별, 2018-2030년
• 항우울제
• 항불안제
• 항경련제
• 노르아드레날린 작용제
• 비정형 항정신병제

제5장 불안장애 및 우울증 치료 시장 : 적응증 비즈니스 분석

• 적응증 시장 점유율, 2024년과 2030년
• 적응증 부문 대시보드
• 시장 규모와 예측과 동향 분석, 적응증별, 2018-2030년
• 우울증
• 불안장애

제6장 불안장애 및 우울증 치료 시장 : 유통 채널 비즈니스 분석

• 유통 채널 시장 점유율, 2024년과 2030년
• 유통 채널 부문 대시보드
• 시장 규모와 예측과 동향 분석, 유통 채널별, 2018-2030년
• 병원 약국
• 소매 약국
• 기타

제7장 불안장애 및 우울증 치료 시장 : 지역별, 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 국가별, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 국가별, 2018-2030년
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 덴마크
  • 스웨덴
• 아시아태평양
  • 국가별, 2018-2030년
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 국가별, 2018-2030년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 국가별, 2018-2030년
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 참여자 개요
• 기업의 시장 포지션 분석
• 기업 분류
• 전략 매핑
• 기업 개요/상장 기업
  • Pfizer Inc.
  • H. Lundbeck A/S
  • GSK plc
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc.
  • AbbVie Inc.
  • Sanofi

ksm

영문 목차

영문목차

Anxiety Disorders And Depression Treatment Market Growth & Trends:

The global anxiety disorders and depression treatment market size is estimated to reach USD 19.28 billion by 2030, registering to grow at a CAGR of 3.8% from 2025 to 2030 according to a new report by Grand View Research, Inc. The rising incidence of depression worldwide is anticipated to drive the market growth in the coming years. Increasing adoption of devices and psychotherapies has resulted in the declining demand for antidepressants in recent years.

The rising geriatric population prone to depression and surging prevalence of anxiety disorders, including phobias and generalized anxiety disorder, are further contributing toward the growing demand for antidepressants to treat mental illnesses over the forecast period. Moreover, the introduction of technologically advanced therapies, such as medical implants used for brain stimulation and virtual reality exposure therapies using smartphone-based applications, furnish patients with innovative treatment alternatives.

Anxiety Disorders And Depression Treatment Market Report Highlights:

• The antidepressants segment dominated the market and accounted for the highest revenue share of 32.4% in 2024.
• Anxiety led the market with a revenue share of 55.4% in 2024, fueled by the increased presence of phobias, social anxiety disorders, and other similar conditions in both established and growing economies.
• The retail pharmacies segment held the largest market share of 55.4% in 2024 due to patients' preference for nearby, trustworthy pharmacies.
• North America anxiety disorders and depression treatment market dominated the global market with a revenue share of 37.6% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Type
  • 1.2.2. Indication
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Anxiety Disorders and Depression Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis

Chapter 4. Anxiety Disorders and Depression Treatment Market: Drug Type Business Analysis

• 4.1. Drug Type Market Share, 2024 & 2030
• 4.2. Drug Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
• 4.4. Antidepressants
  • 4.4.1. Antidepressants Market, 2018 - 2030 (USD Million)
• 4.5. Anxiolytics
  • 4.5.1. Anxiolytics Market, 2018 - 2030 (USD Million)
• 4.6. Anticonvulsants
  • 4.6.1. Anticonvulsants Market, 2018 - 2030 (USD Million)
• 4.7. Noradrenergic Agents
  • 4.7.1. Noradrenergic Agents Market, 2018 - 2030 (USD Million)
• 4.8. Atypical Antipsychotics
  • 4.8.1. Atypical Antipsychotics Market, 2018 - 2030 (USD Million)

Chapter 5. Anxiety Disorders and Depression Treatment Market: Indication Business Analysis

• 5.1. Indication Market Share, 2024 & 2030
• 5.2. Indication Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 5.4. Depression
  • 5.4.1. Depression Market, 2018 - 2030 (USD Million)
• 5.5. Anxiety
  • 5.5.1. Anxiety Market, 2018 - 2030 (USD Million)

Chapter 6. Anxiety Disorders and Depression Treatment Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2024 & 2030
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Anxiety Disorders and Depression Treatment Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Framework
    • 7.4.2.3. Competitive Insights
    • 7.4.2.4. U.S. Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Framework
    • 7.4.3.3. Competitive Insights
    • 7.4.3.4. Canada Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory Framework
    • 7.4.4.3. Competitive Insights
    • 7.4.4.4. Mexico Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Framework
    • 7.5.2.3. Competitive Insights
    • 7.5.2.4. UK Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Framework
    • 7.5.3.3. Competitive Insights
    • 7.5.3.4. Germany Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Framework
    • 7.5.4.3. Competitive Insights
    • 7.5.4.4. France Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Regulatory Framework
    • 7.5.5.3. Competitive Insights
    • 7.5.5.4. Italy Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Regulatory Framework
    • 7.5.6.3. Competitive Insights
    • 7.5.6.4. Spain Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Norway
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Regulatory Framework
    • 7.5.7.3. Competitive Insights
    • 7.5.7.4. Norway Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Regulatory Framework
    • 7.5.8.3. Competitive Insights
    • 7.5.8.4. Denmark Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Sweden
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Regulatory Framework
    • 7.5.9.3. Competitive Insights
    • 7.5.9.4. Sweden Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Framework
    • 7.6.2.3. Competitive Insights
    • 7.6.2.4. Japan Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Framework
    • 7.6.3.3. Competitive Insights
    • 7.6.3.4. China Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Framework
    • 7.6.4.3. Competitive Insights
    • 7.6.4.4. India Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Framework
    • 7.6.5.3. Competitive Insights
    • 7.6.5.4. South Korea Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Framework
    • 7.6.6.3. Competitive Insights
    • 7.6.6.4. Australia Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Regulatory Framework
    • 7.6.7.3. Competitive Insights
    • 7.6.7.4. Thailand Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Framework
    • 7.7.2.3. Competitive Insights
    • 7.7.2.4. Brazil Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Framework
    • 7.7.3.3. Competitive Insights
    • 7.7.3.4. Argentina Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Framework
    • 7.8.2.3. Competitive Insights
    • 7.8.2.4. South Africa Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Framework
    • 7.8.3.3. Competitive Insights
    • 7.8.3.4. Saudi Arabia Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Framework
    • 7.8.4.3. Competitive Insights
    • 7.8.4.4. UAE Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Regulatory Framework
    • 7.8.5.3. Competitive Insights
    • 7.8.5.4. Kuwait Anxiety Disorders and Depression Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Pfizer Inc.
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. H. Lundbeck A/S
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. GSK plc
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Merck & Co., Inc.
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Eli Lilly and Company
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. AstraZeneca
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Bristol-Myers Squibb Company
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Johnson & Johnson Services, Inc.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. AbbVie Inc.
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Sanofi
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives

관련자료